The approval is the first that the Food and Drug Administration has granted for a drug intended to treat eosinophilic esophagitis, a chronic immune disorder.
The two companies are collaborating to research, develop and launch new small-molecule drug candidates aimed at treating obesity and related comorbidities.
As the pandemic continues to impact the globe, the agency has kept busy issuing EUAs for potential treatments, and cited sellers of unapproved treatments.
Regeneron and UK Biobank announce human sequencing data resource for global research and to accelerate improved patient care through outcome algorithms.
